



Original Article

The Role of the Carotid Doppler Examination in the Evaluation of Atherosclerotic Changes in β -Thalassemia Patients

Hoda A. Abdelsamei¹, Ashraf M. El-Sherif², Ahlam M. Ismail³ and Gehan L. Abdel Hakeem⁴

¹ Diagnostic Radiology Department, South Valley University.

² Diagnostic Radiology Department and, Minia University.

³ Pediatrics Department South Valley University.

⁴ Pediatrics Department Minia University Egypt.

Competing interests: The authors have declared that no competing interests exist.

Abstract. Background: Iron overload in patients with beta-thalassemia major (BTM) lead to alterations in the arterial structures and the thickness of the carotid arteries. Doppler ultrasound scanning of extra-cranial internal carotid arteries is non-invasive and relatively quick to perform and may identify children at increased risk of stroke who would otherwise be missed. Increased carotid artery intima media thickness (CIMT) is a structural marker for early atherosclerosis and correlates with the vascular risk factors and to the severity and extent of coronary artery disease.

Objective: To evaluate the role of carotid Doppler examination and CIMT measurement as a predictor of atherosclerotic changes in BTM children with iron overload.

Patients and Methods: Sixty two children with BTM and, thirty age and sex matched normal controls were included. Complete blood count, ferritin, serum cholesterol were done, as well as carotid Doppler ultrasonography to measure the CIMT in both patients and controls.

Results: CIMT of thalassemic patients was significantly increased compared to controls ($p=0.001$). There was a significant positive correlation between CIMT and patient's age, the duration from first blood transfusion, serum cholesterol and, iron overload parameters as serum ferritin, frequency of blood transfusion, iron chelation. The length of the transfusion period was the highest risk factor and splenectomy was a further risk factor. Significant negative correlation was found between CIMT and hematocrit value while no significant correlation was found between CIMT and weight, height, BMI centiles and Hb level.

Conclusion: Carotid Doppler is very useful in measurement of CIMT that increased in thalassemic patients that shows a strong relationship with features of iron overload. Routine Doppler measurement of CIMT in these patients is recommended to predict early atherosclerotic changes as well as in follow-up.

Citation: Abdelsamei H.A., El-Sherif A.M., Ismail A. M., Abdel Hakeem G.L. The Role of the Carotid Doppler Examination in the Evaluation of Atherosclerotic Changes in β -Thalassemia Patients. *Mediterr J Hematol Infect Dis* 2015, 7(1): e2015023, DOI: <http://dx.doi.org/10.4084/MJHD.2015.023>

Published: February 10, 2015

Received: December 02, 2014

Accepted: February 02, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Gehan L. Abdel Hakeem. Pediatrics Department Minia University Egypt. E-mail: gehanlotfy72@yahoo.com

Introduction. Thalassemia syndromes are groups of heterogeneous hereditary diseases characterized by a decrease or a total absence of synthesis of α - and/or β -globin chains composing the hemoglobin protein in red blood cells (RBCs).¹ They are classified according to the type of deficient globin chain as α - and β -

thalassemia.² In β -thalassemia, the severity of the pathophysiology depends on the level of β -globin chain deficiency, which leads to an excess of α -globin chains.³ Consequently, thalassaemic RBCs are hypochromic and microcytic and have a shorter half-life, leading to anemia.⁴ Three clinical phenotypes of decreasing severity have been established: a transfusion-dependent state, thalassemia major, a moderate phenotype, thalassemia intermedia, and a benign heterozygous condition, thalassemia minor. Clinical features, in addition to the RBC anomalies, are heterogeneous, and patients display several systemic manifestations.⁵ According to the so called "iron hypothesis," iron is believed to be detrimental for the cardiovascular system, thus promoting atherosclerosis development and progression.⁶ Iron overload in patients with beta-thalassemia major lead to alterations in the arterial structures and the thickness of the carotid arteries. In addition, carotid thickness positively correlated with age, Hb, ferritin and cholesterol levels in these patients. As a result, coronary artery diseases (CAD) is a quite common cardiovascular complication in thalassaemics. Patients on a regular transfusion regimen progressively develop clinical manifestations of iron overload associated with heart dysfunction and left ventricular failure if inadequately chelated.⁷ Doppler ultrasound scanning of extracranial internal carotid arteries is non-invasive and relatively quick to perform and may identify children at increased risk of stroke who would otherwise be missed.⁸ High resolution ultrasound is a reliable, method for detecting early structural and functional atherosclerotic changes in the arterial wall.⁹ Increased carotid artery intima media thickness (CIMT) is a structural marker for early atherosclerosis, and it correlates with the vascular risk factors and to the severity and extent of coronary artery disease.^(10,11)

The study objectives: This study aimed to evaluate the role of carotid Doppler examination and CIMT measurement as a predictor to atherosclerotic changes in B thalassemia major (BTM) children with iron overload.

Patients and Methods. This is a cross sectional case control study. Sixty two children with BTM were selected from the pediatric hematology outpatient clinics in Qena and Menia University hospitals as well as 30 healthy normal age and sex matched controls in the period from May 2013 to September 2014. Diagnostic criteria, assessment and management of thalassaemic children were based on Guidelines for the Clinical Management of Thalassemia.¹² The study was approved by the local research ethics committee of the two hospitals and written informed consent was obtained from the parents of all children to share in the study. Included patients with B thalassemia proved by clinical and laboratory investigations, frequent blood transfusion, chelation therapy. Patients with familiar

hypercholesterolemia (confirmed by history), cardiovascular symptoms suggesting the presence of heart failure or atherosclerotic changes and patients with chronic systemic illness were excluded. All patients were subjected to the following work-up assessment:

I. The history including the duration of the illness since the first blood transfusion, the frequency of blood transfusion (frequent ≥ 2 times/month) and the intake of iron chelating agents. Chelation therapy is initiated when serum ferritin levels reach approximately 1000 ng/mL (subcutaneous deferoxamine, oral deferoxamine or combination of both) and patients were classified as adequately chelated, poorly chelated or non-chelated according to serum ferritin level, frequency of blood transfusion and regularity of chelation.

II. Clinical examination including general, chest, heart and abdominal examination. Patient's anthropometric measurements were plotted on growth charts (Official 2000 centers for centers for disease control (CDC) growth charts, created by the National Center for Health Statistics (NCHS)).¹³

III. Laboratory and radiological investigations including complete blood count, hemoglobin electrophoresis, serum levels of ferritin and iron and iron binding capacity all were done at the time of the study. Abdominal ultrasound was performed for detection of the hepatomegaly and/or splenomegaly.

Carotid duplex study: All patients and controls were subjected to B-mode and color-coded duplex sonography of their extra-cranial carotid and vertebral arteries. All studies were performed using a LOGIC P6 ultrasound system (GE medical systems, Milwaukee, WI) with a 12.0-MHz linear array transducer. All ultrasound examinations were performed by a single experienced vascular radiologist who was unaware of the clinical and laboratory details of the examined children. Examination started by locating the common carotid artery (CCA) in the lower neck in the transverse plane. The CCA is followed proximally until the transducer is blocked by the clavicle, and caudal angulations is tried to evaluate the common carotid origin if possible. The CCA continues upwards till it widens to form the carotid bulb; then it bifurcates into internal and external branches. The transducer is then rotated 90 degrees to be parallel to the CCA to have longitudinal scanning of the CCA, the bifurcation, the internal carotid artery (ICA) and external carotid artery (ECA). The ICA was then followed distally as far as possible and optimally until it is lost behind the mandible. The vessels were evaluated meticulously for the presence of subintimal lucency, and atherosclerotic plaques that bulge into the lumen, followed by measuring the intimal plus medial thickness (IMT). IMT was measured in 1-cm segment proximal to the dilation of the carotid bulb, referred to as CCA, and always in plaque-free segments. For each subject, three measurements on both sides were obtained on the

anterior, lateral, and posterior projection of the far wall. Values for the different projections and right and left arteries were then averaged. Two end-diastolic frames were selected and analyzed for mean CIMT, and the average reading from these two frames was calculated for both right and left carotid arteries. The average of the two sides was considered the patient's overall mean CIMT. Statistical analysis: The data were statistically analyzed using the SPSS software package, version 16 (SPSS Inc., Chicago, IL, USA) on a personal computer. Numerical data were expressed as range, mean± SD, median, and percentiles. Non numerical data were expressed as frequencies. Comparative studies were done using Student t test and chi square test. (p value < 0.05 was considered significant). Pearson correlation test was used to detect correlation between different parameters. In addition, multiple regression analysis was done to identify the most significant risk factors.

Results. Demographic, clinical and laboratory data for patients and controls are shown in **table 1**. No significant difference between patients and controls

regarding age or gender, while significant difference was found regarding weight, height and BMI centiles, Hb level, hematocrite value, serum ferritin and serum cholesterol. The duration since first transfusion ranged from 1.5-13years with a mean of 7.26± 3.7. Thirty two patients (51.6%) had frequent blood transfusion, 24 patients (38.7%) were adequately chelated, and 24 patients (38.7%) undergone splenectomy operation. **Table 2** shows comparison between patients and controls regarding CIMT. There was a significant difference between studied patients and controls regarding CIMT measurements ($p = 0.001$). As shown in **table 3** and **figures 1 and 2**, significant positive correlation was found between CIMT and patient's age, duration since the first blood transfusion, serum ferritin and serum cholesterol. Significant negative correlation was found between CIMT and hematocrit value while no significant correlation was found between CIMT regarding weight, height, BMI centiles and Hb level. CIMT was significantly increased in BTM children in relation to children with frequent blood transfusion, patients who were poorly chelating or had splenectomy

Table 1. Demographic, clinical and laboratory data for studied patients and control.

| Parameter | | Patients (No: 62) | Control (N: 30) | P value# |
|--|--|---|--|----------|
| Age (years) | Range mean± SD | 3-14 years 8.05±3.12 | 3-13 6.5±3.5 | 0.628 |
| Gender | Male Female | 34 (54.8%) 28 (45.2%) | 19 (63.3%) 11 (36.7%) | 0.442 |
| Weight (kg) for age centile | Range mean± SD Median | 5 th -50 th 23.4±15.2 21 | 25 th -90 th 48±20.95 25 | 0.025* |
| Height (cm) for age centile | Range mean± SD Median | 5 th -90 th 35.8±25.4 111 | 25 th -90 th 47.17±15.52 114 | 0.001* |
| BMI (kg/m ²) centile | Range mean± SD Median | 3-97 31.1±37.7 14.51 | 10 th -97 th 68.4±22.15 16.3 | 0.001* |
| Duration since the 1 st transfusion (years) | Range mean ± SD | 1.5-13 7.26±3.7 | ----- | |
| Frequency of blood transfusion | Frequent Infrequent | 32 (51.6%) 30 (48.4%) | ----- | |
| Iron chelation | Adequately chelated Poorly chelated Not chelated | 24 (38.7%) 22 (35.5%) 16 (25.8%) | ----- | |
| Surgical splenectomy | Done Not done | 24 (38.7%) 38 (61.3) | ----- | |
| Hb level (gm/dl) | Range mean± SD | 7-11.5 9.01±1.2 | 11-13.8 12.2 ± 0.7 | 0.001* |
| Hematocrit value (%) | Range mean± SD | 21-32 26.4±3.1 | 35-40.1 38.1 ± 1.2 | 0.001* |
| Serum ferritin (ng/dl) | Range mean± SD | 140-1900 890±194.3 | 36-97 67.5 ± 12.5 | 0.001* |
| Serum cholesterol (mg/dl) | Range mean±SD | 50-980 541.1±124.5 | 55-99 78± 13.4 | 0.001* |

#Student t- test * significant

Table 2. Comparison between patients and controls regarding CIMT(mm).

| Group | Range | Mean ±SD | P value# |
|-----------------|---------|------------|----------|
| Patients(No:62) | 0.4-0.6 | 0.48± 0.02 | 0.001* |
| Controls(No:30) | 0.3-0.4 | 0.32± 0.05 | |

#Student t- test * significant

Table 3. Correlations between CIMT and thalassemic patients regarding their clinical and laboratory data.

| Cases | CIMT (mm) (0.46±0.02) | |
|--|--------------------------|--------|
| | P value# | r^ |
| Age (years) | 0.001* | 0.928 |
| Weight (kg) centile | 0.27 | -0.165 |
| Height (cm) centile | 0.84 | -0.031 |
| BMI (kg/m ²) | 0.28 | -0.163 |
| Duration since first transfusion (years) | 0.001* | 0.927 |
| Hb level (gm/dl) | 0.07 | -0.332 |
| Hematocrit (%) | 0.03* | -0.385 |
| Serum ferritin (ng/dl) | 0.001* | 0.763 |
| Serum cholesterol (mg/dl) | 0.001* | 0.830 |

^ Pearson Correlation *significant




Figure 1. Correlation between CIMT and duration since first transfusion




Figure 2. Correlation between CIMT and serum ferritin.

Table 4. CIMT in relation to clinical data in the studied cases.

| Clinical parameter | Finding | Number and % | CIMT | |
|-----------------------------|--------------------------|--------------|-----------|---------|
| | | | Mean ± SD | P value |
| Blood transfusion frequency | Frequent (every 2 weeks) | 32 (51.6%) | 0.53±0.51 | 0.03* |
| | Infrequent | 30 (48.4%) | 0.37±0.19 | |
| Iron chelating agents | Chelating | 24 (38.7%) | 0.39±0.04 | 0.02* |
| | Poorly chelating | 22 (35.5%) | 0.51±0.71 | |
| Splenectomy | Done | 24 (38.7%) | 0.54±0.10 | 0.04* |
| | Not done | 38 (61.3) | 0.37±0.07 | |

* Significant $p < 0.05$.




Figure 3. a) Long-axis magnified view of the normal carotid wall anatomy on U/S. The intima and adventia produces echogenic parallel lines (arrows) with an intervening echo void representing the media. b) Long-axis view and Doppler spectrum of the right CCA showing normal intima-media thickness of 0.3 mm in a 10-year-old healthy child.




Figure 4. Long-axis view and Doppler spectrum of the right CCA showing increased intima-media thickness of 0.6-mm in an 11-year-old child with thalassemia.



Figure 5. Long-axis view of the right CCA showing increased intima-media thickness of 0.6-mm in a 9-year-old child with thalassemia.

Table 5. Risk factors of increased CIMT in B thalassemic patients.

| Risk factors of increased CIMT in B thalassemic patients (Multiple regression analysis) | | | |
|--|-----------------------------------|---------|------------------|
| Variable | Standardized Coefficients β | P value | Total adjustment |
| Duration since 1 st transfusion (years) | 0.73476 | .001 | 4.069 |
| Regularity of iron chelation | 0.444871 | .001 | 3.693 |
| Presence of splenectomy | -0.14279 | 0.204 | -1.307 |
| Hematocrit value (%) | 0.087844 | .219 | 1.261 |
| Serum ferritin (ng/ml) | -0.16842 | .156 | -1.464 |
| Serum cholesterol (mg/dl) | -0.11444 | .399 | -.859 |




Figure 6. Risk factors of increased CIMT in B thalassemic patients (Multiple regression analysis).

(Table 4). Figures 3-5 show the ultrasonographic CIMT measurements and the Doppler spectrum of the carotid vessels in healthy controls and in patients with BTM. Table 5 and figure 6 display the risk factors increasing CIMT in thalassemic patients. Duration of illness carries the highest risk factor followed by the inadequate iron chelation therapy.

Discussion. Beta-thalassemia is a group of hereditary blood disorders first described by Cooley and Lee.¹⁴ With the increased life span of BTM patients, coronary artery disease may emerge as one of the important cardiovascular complications.¹⁵ Studies have suggested a link between iron load and risk of atherosclerosis. The present study was undertaken to evaluate the role of carotid Doppler examination and CIMT measurement as a predictive to atherosclerotic changes in BTM children with iron overload. Our data show that the CIMT of thalassemic patients was significantly increased compared to controls. This finding is supported by the results of some previous studies;¹⁶⁻¹⁸ Cheung et al.,¹⁹ found an increase in the CIMT in patients with BTM compared to controls, Tantawy et al, 2009¹⁷ and Gullu et al,¹⁸ found the same results in their study, and Adly et al.¹⁹ reported that Carotid IMT measurements were significantly but slightly higher in the BTM group than that in the controls (0.57 ± 0.07 vs. 0.54 ± 0.04 , $P = 0.04$) and that CIMT is increased in patients with BTM. On the other hand, a previous study, carried out by Cusmà et al.,²⁰ comparing the CIMT between the thalassemic patients and healthy subjects (0.67 ± 0.20 mm vs 0.66 ± 0.15 mm), shown no significant difference. The conclusion of this research was that 2-dimensional strain and echo-tracking might be more accurate than standard echocardiography and vascular parameters in the early identification of cardiovascular involvement.

The development of carotid artery wall hypertrophic remodeling, found in thalassemic patients, is characterized by an increase in both total wall thickness and wall-to-lumen ratios; hemolysis likely contributed to the pathophysiology of both endothelial dysfunction as well as vascular, structural and mechanical, changes.²² In our study, there was significant statistical correlation between CIMT and

patient's age, ferritin, and total cholesterol levels but there was no significant difference of CIMT in relation to patient's hemoglobin level. This also comes in harmony with the study of Tantawy et al.¹⁷ who reported that in thalassemic patients, CIMT was positively correlated with age, ferritin and cholesterol levels, and that atherogenic lipid profiles in young thalassemic patients with increased CIMT highlights their importance as prognostic factors for vascular risk stratification. These findings are further supported by Gursel et al.,²² who investigated the relationship between chronic hemolysis and increased body iron burden and the development of premature atherosclerosis by using CIMT, ferritin, serum lipid profile. They concluded that Subclinical atherosclerosis in children with β -thalassemia major begins early in life, and these children are at risk for development of premature atherosclerosis. Iron overload is usually associated with regular blood transfusions which lead to transfusional haemosiderosis in patients with chronic anemia in children with BTM.²³ These changes occur initially in reticulo-endothelial system and secondary in all parenchymal organs, mainly heart, pancreas, pituitary gland, and gonads, with cytotoxic effects.²⁴ So, accumulation of iron has been implicated as a risk of cardiovascular disease, because of the catalytic role of iron, causing oxidative stresses on the vessel wall.²⁵⁻²⁷ We also found that CIMT was significantly different in children with BTM in relation to features suggestive of iron overload including duration since first blood transfusion which carries the highest risk factor of increasing CIMT, frequency of blood transfusion, irregular use of iron chelating agents in patients who were poorly chelating or had splenectomy. This comes in harmony with the results of a previous study that was carried out by Cheung et al.,²⁸ who found that iron overloading in patients with beta-thalassemia major results in alterations of arterial structures with disruption of elastic tissue and calcification. This finding is also supported by Ramakrishna et al.,²⁹ as well as other epidemiological studies concluding that iron is an important factor in the process of atherosclerosis²⁷ and that CIMT is considered an early

marker of atherosclerotic process and is currently used to assess the presence and the progression of atherosclerosis.^{30,31} A significant positive correlation was found in this study between duration since first blood transfusion and CIMT, the longer the duration, the more atherogenesis as reflected by increased CIMT. And also, there was another significant positive correlation between serum ferritin levels and CIMT. Duration of illness carries the highest risk factor of increasing CIMT followed by the iron chelation therapy guided by serum ferritin. The catalytic role of iron in free radical reactions causes oxidation of LDL and may be an important factor in the formation of atherosclerotic lesions. Studies have shown that iron can stimulate lipid peroxidation in vitro and in vivo.²⁹ Oxidized LDL is followed by accumulation of lipids in cells and the formation of foam cells, characteristic of early atherosclerosis. Thereby, oxidized LDL has cytotoxic capacity that induces changes in endothelial cells with loss of endothelial integrity, which could facilitate further accumulation of both circulating monocytes and LDL and thus promote the progression of the atherosclerotic lesion.³²⁻³⁵

Conclusion. Carotid Doppler is very useful method in measurement of CIMT that increased in thalassemic patients. CIMT shows a strong relationship with features of iron overload and atherosclerotic changes. Duration of illness carries the highest risk factor of increasing CIMT followed by inadequate iron chelation therapy. Prevention of the progression of atherosclerosis in early stages is important by decreasing body iron load in the thalassemic patients. We recommend the routine use of Doppler measurement of CIMT in BTM patients as a non-invasive diagnostic method to predict early atherosclerotic changes as well as in the follow-up to prevent progression of atherosclerosis. Reducing hyper-lipidemia and body iron load in the thalassemic patients by dietary restriction or pharmacological therapy and good compliance of iron chelating agents is also recommended.

References:

1. Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H. The Molecular Basis of Blood Diseases. Philadelphia, PA: WB Saunders, 2001, p. 183–273
2. Tuzmen S, Schechter AN. Genetic diseases of hemoglobin: diagnostic methods for elucidating beta-thalassemia mutations. *Blood Rev* 15: 19–29, 2001 <http://dx.doi.org/10.1054/blre.2001.0147> PMID:11333136
3. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. *Nat Rev Genet* 2: 245–255, 2001 <http://dx.doi.org/10.1038/35066048> PMID:11283697
4. Hoffman R. Hematology: Basic Principles and Practice. New York: Churchill-Livingstone, 2005 Ekatherina Stoyanova, Marie Trudel, Hady Felfly, Damien Garcia, Guy Cloutier. Characterization of circulatory disorders in β -thalassemic mice by noninvasive ultrasound biomicroscopy: *Physiological Genomics* Published 1 March 2007 Vol. 29no. 1,84
5. Francesca Vinchi I, Martina U. Muckenthaler, Milene C. DaSilva, György Balla, József Balla and Viktória Jen. "Atherogenesis and iron: from epidemiology to cellular level. Published: 05 May 2014 <http://dx.doi.org/10.3389/fphar.2014.0009>
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A: "Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine". *Haematologica* 2004, 89:1187-93. PMID:15477202
7. Colin R. Deane, David Goss, Jack Bartram, Keith R.E. Pohl, Susan E. Height, Naomi Sibtain, Jozef Jarosz, Swee Lay Thein, and David C. Rees. Extracranial internal carotid arterial disease in children with sickle cell anemia: *Haematologica*. Aug 2010; 95(8): 1287–1292. Published online Mar 10, 2010. doi: <http://dx.doi.org/10.3324/haematol.2010.022624>
8. Aggoun Y, Szezepanski I, Bonnet D. Non invasive assessment of arterial stiffness and risk of atherosclerotic events in children. *Pediatr Res*. 2005;58(2):173-8.

- <http://dx.doi.org/10.1203/01.PDR.0000170900.35571.CB>
PMid:16055929
9. Järvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type-1 diabetes. *Circulation*.2004; 109(14):1750-5. <http://dx.doi.org/10.1161/01.CIR.0000124725.46165.2C>
PMid:15023875
 10. Cheung YF. Arterial Stiffness in Children and Teenagers: An Emerging Cardiovascular Risk Factor. *HK J Paediatr*, 2005;10:299-306.
 11. Maria-DomenicaCappellini, Alan Cohen, AndroullaEleftheriou, Antonio Piga, John Porter andAliTaher: Guidelines for the Clinical Management of Thalassaemia. *Thalassaemia International Federation* 2008. 2nd Revised edition
 12. Official 2000 centers for centers for disease control (CDC) growth charts, created by the National Center for Health Statistics (NCHS). www.cdc.gov/nchs
 13. Cooley TB, Lee P: "A series of cases of splenomegaly in children with anemia and peculiar changes". *Trans Am PediatrSoc* 1925, 37:29-30.
 14. Aessopos A, Farmakis D, Tsironi M, et al. Endothelial function and arterial stiffness in sickle-thalassemia patients. *Atherosclerosis*. 2007;191(2):427-32. <http://dx.doi.org/10.1016/j.atherosclerosis.2006.04.015>
PMid:16712855
 15. Cheung YF, Chow PC, Chan GC, Ha SY. Carotid intima-media thickness is increased and related to arterial stiffening in patients with b-thalassaemia major. *Br J Haematol*. 2006;135(5):732-4. <http://dx.doi.org/10.1111/j.1365-2141.2006.06349.x>
PMid:17107355
 16. Tantawy A.G Azza, Adly A.M Amira, El Maaty G.A Mohamed and Amin A.G. Shatha.Subclinical Atherosclerosis In Young β -thalassemia Major Patients. *Hemoglobin*. 2009; 33(6):463-74. <http://dx.doi.org/10.3109/03630260903343616> PMid:19958191
 17. Gullu H, Caliskan M, Caliskan Z, Unler GK, Ermisler E, Ciftci O, Guven A, Muderrisoglu H. "Coronary Microvascular function, Peripheral Endothelial Function and Carotid IMT in beta-thalassemia minor"*Thromb Res*.2013 Jun;131(6):e247-52. Epub 2013 May 15. <http://dx.doi.org/10.1016/j.thromres.2013.03.013>
 18. Adly AA, El-Sherif NH, Ismail EA, El-Zaheer YA, Farouk A, El-Refaei AM, WahbaMS."Vascular Dysfunction in Patients With Young β -Thalassemia: Relation to Cardiovascular Complications and Subclinical Atherosclerosis".*ClinApplThrombHemost*. 2014 Jul 2. pii: 1076029614541515. [Epub ahead of print] <http://dx.doi.org/10.1177/1076029614541515> PMid:24989711
 19. CsmàPiccione M1, Piraino B, Zito C, Khandheria BK, Di Bella G, De Gregorio C, Oreto L, Rigoli L, Ferrà V, Salpietro CD, CarerjS.."Early identification of cardiovascular involvement in patients with β -thalassemia major" *Am J Cardiol* 2013 Oct 15;112(8):1246-51. Epub 2013 Jul 19. <http://dx.doi.org/10.1016/j.amjcard.2013.05.080>
 20. Stoyanova E, Trudel M, Felfly H, Lemsaddek W, Garcia D, et al. Vascular Endothelial Dysfunction in β -Thalassemia Occurs Despite Increased eNOS Expression and Preserved Vascular Smooth Muscle Cell Reactivity to NO. *PLoS2012 ONE* 7(6): e38089. <http://dx.doi.org/10.1371/journal.pone.0038089>
 21. Gursel OI, Kurekci AE, Tascilar E, Ileri T, Altun D, Tapan S, Kurt I, Kocaoglu M, Aydin A, Okutan V, Ozcan O. Premature Atherosclerosis in Children With β -Thalassemia Major" *Journal of Pediatric Hematology/Oncology* 2012; 34(8):630-4. PMid:23108004
 22. McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, et al.: Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. *Health Technol Assess* 2009, 13(1):iii-iv.ix-xi, 1-121.
 23. Christoforidis A, Haritandi A, Tsitouridis I, Tsatra I, Tsantali H, KarydaS,Dimitriadis AS, Athanassiou-Metaxa M: Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI inyoungthalassemic patients. *J PediatrHematolOncol* 2006, 28(5):311-5. <http://dx.doi.org/10.1097/01.mph.00000212915.22265.3b>
PMid:16772883
 24. Papanikolaou G, Pantopoulos K: Iron metabolism and toxicity. *ToxicolApplPharmacol* 2005, 202(2):199-211. <http://dx.doi.org/10.1016/j.taap.2004.06.021> PMid:15629195
 25. Qayyum R, Schulman P: Iron and atherosclerosis. *ClinCardiol* 2005, 28(3):119-22. PMid:15813617
 26. Shah SV, Alam MG: Role of iron in atherosclerosis. *Am J Kidney Dis* 2003, 41(3 Suppl 1):S80-83. <http://dx.doi.org/10.1053/ajkd.2003.50091> PMid:12612959
 27. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. *Circulation* 2002; 106:2561-6. <http://dx.doi.org/10.1161/01.CIR.0000037225.92759.A7>
PMid:12427652
 28. Ramakrishna G, Rooke TW, Cooper LT: Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. *Vasc Med*2003, 8(3):203-10. <http://dx.doi.org/10.1191/1358863x03vm493ra> PMid:14989563
 29. Ferrara DE, Taylor WR: Iron chelation and vascular function: in search of the mechanisms. *ArteriosclerThrombVascBiol* 2005, 25(11):2235-7. <http://dx.doi.org/10.1161/01.ATV.0000189303.45609.1f>
PMid:16258147
 30. Druke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. *Circulation* 2002, 106(17):2212-7. <http://dx.doi.org/10.1161/01.CIR.0000035250.66458.67>
PMid:12390950
 31. Gaenger H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, Weiss G: Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. *J Am Coll Cardiol*2002, 40(12):2189-94. [http://dx.doi.org/10.1016/S0735-1097\(02\)02611-6](http://dx.doi.org/10.1016/S0735-1097(02)02611-6)
 32. deValk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. *Arch Intern Med*. 1999; 159(14):1542-8. <http://dx.doi.org/10.1001/archinte.159.14.1542>
 33. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol.Modifications of low-density lipoprotein that increaseits atherogenicity. *N Engl J Med*.1989;320(14):915-924. <http://dx.doi.org/10.1056/NEJM198904063201407>
 34. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. *Am J ClinNutr*. 1993;57(5 Suppl):715S-724S. Discussion 724S-725S.